Normal View Dyslexic View
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
16 August 2024
Randomized clinical trials General
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR et al .
Published on: 16 August 2024
Article ID: rct273


.png)





.jpg)




